ArticleBMC infectious diseases2026
The outcomes of isoniazid prophylaxis in LTBI high-risk pediatric patients undergoing hematopoietic stem cell transplantation.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundTuberculosis (TB) infection poses a significant risk to patients undergoing hematopoietic stem cell transplantation (HSCT), particularly those with latent TB infection (LTBI). Despite the recognized vulnerability of these patients, data on TB prophylaxis and its outcomes in pediatric HSCT recipients remain limited.
methodsWe conducted a retrospective study of 714 pediatric HSCT recipients at Shenzhen Children’s Hospital from January 2018 to December 2021. Patients were categorized into LTBI high-risk and low-risk groups based on positive interferon-gamma release assay (IGRA) results and radiological findings indicative of prior TB infection. The high-risk group received isoniazid (INH) prophylaxis, while the low-risk group did not receive routine TB prophylaxis. Patient outcomes, including TB incidence, drug toxicity, and post-HSCT complications, were monitored over two years.
resultsThe high-risk group comprised of 69 patients, and the low-risk group included 620 patients. No significant differences were observed between the groups regarding patient characteristics, HSCT type, or donor source. Over the follow-up period, no confirmed TB cases occurred in the high-risk group receiving INH prophylaxis, whereas one patient (0.31%) in the low-risk group developed TB. Mild hepatic toxicity (grade 1) was observed in 27.54% of patients in the high-risk group, with one case of grade 3 toxicity (1.45%) requiring INH discontinuation. No severe renal toxicity or fatal adverse events were reported. Post-HSCT complications included acute graft-versus-host disease (11.59%), chronic graft-versus-host disease (13.04%), and invasive fungal infections (4.35%), with no significant differences in outcomes between the groups. Full graft chimerism was achieved in 98.55% of patients, and no deaths occurred during the study period.
conclusionsINH prophylaxis effectively prevented TB reactivation in LTBI high-risk pediatric HSCT recipients without significant adverse events. A risk-based stratification approach to TB prophylaxis is both safe and effective, minimizing unnecessary drug exposure while protecting vulnerable patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.